91.47
-0.11 (-0.12%)
| Previous Close | 91.58 |
| Open | 91.53 |
| Volume | 585,515 |
| Avg. Volume (3M) | 1,067,432 |
| Market Cap | 6,359,616,512 |
| Price / Earnings (TTM) | 15.19 |
| Price / Earnings (Forward) | 14.18 |
| Price / Sales | 4.75 |
| Price / Book | 6.42 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Profit Margin | 20.37% |
| Operating Margin (TTM) | 28.23% |
| Diluted EPS (TTM) | 4.36 |
| Quarterly Revenue Growth (YOY) | 10.50% |
| Quarterly Earnings Growth (YOY) | -0.70% |
| Total Debt/Equity (MRQ) | 57.10% |
| Current Ratio (MRQ) | 5.52 |
| Operating Cash Flow (TTM) | 544.75 M |
| Levered Free Cash Flow (TTM) | 290.56 M |
| Return on Assets (TTM) | 15.35% |
| Return on Equity (TTM) | 32.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Lantheus Holdings, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.5 |
| Average | 0.80 |
|
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 2.29% |
| % Held by Institutions | 112.17% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 122.00 (B. Riley Securities, 33.38%) | Buy |
| Median | 119.50 (30.64%) | |
| Low | 117.00 (Truist Securities, 27.91%) | Buy |
| Average | 119.50 (30.64%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 48.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 08 May 2025 | 117.00 (27.91%) | Buy | 0.000 |
| 27 Feb 2025 | 127.00 (38.84%) | Buy | 91.49 | |
| B. Riley Securities | 21 Mar 2025 | 122.00 (33.38%) | Buy | 97.71 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 May 2025 | Announcement | Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update |
| 06 May 2025 | Announcement | Lantheus Announces Sale of SPECT Business to SHINE Technologies |
| 30 Apr 2025 | Announcement | Lantheus Announces Alzheimer’s Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies |
| 23 Apr 2025 | Announcement | Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 a.m. Eastern Time |
| 01 Apr 2025 | Announcement | Lantheus Completes Acquisition of Evergreen Theragnostics |
| 26 Feb 2025 | Announcement | Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance |
| 21 Feb 2025 | Announcement | Lantheus to Present at Upcoming Investor Conferences |
| 12 Feb 2025 | Announcement | Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |